1. Scrip
  2. >>Therapy Areas

US FDA rejects Teva's petition to block generic Copaxone

 
• By Sue Sutter

The US FDA has rebuffed, for now, Teva Pharmaceutical Industries' bid to block approval of generic competition to its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate).

The US FDA has rebuffed, for now, Teva Pharmaceutical Industries' bid to block approval of generic competition to its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate).

In denying a citizen's petition submitted by Teva, the agency said it would be inappropriate to set forth specific requirements...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapeutic Category

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 
• By Sushmita Panda

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: 4DMT Fast-Tracks Long-Acting Wet AMD Therapy Trials, Cuts 25% Of Workforce

 
• By Sushmita Panda

4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.